Aquestive Therapeutics Eases Disclosure Requirements for Stockholder Board Nominations

• Aquestive Therapeutics adopted bylaw amendments easing stockholder nomination disclosure requirements, effective Oct. 15, 2026.
• Changes remove disclosure requirements for certain relationships involving nominating stockholders and people acting in concert with nominees or their related parties.
• The revised “Stockholder Associated Person” definition excludes people acting in concert with nominating stockholders or beneficial owners submitting nominations or proposals.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aquestive Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001398733-26-000063), on October 19, 2026, and is solely responsible for the information contained therein.